Navigation Links
JCI online early table of contents: Jan. 19, 2009
Date:1/19/2009

EDITOR'S PICK: Fetal heath affected by mother's diet

In the United States, there has been a recent dramatic rise in the number of children classified as obese and diagnosed with obesity-related diseases, such as type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). One factor thought to contribute to this rise is obesity of the mother during pregnancy. However, a team of researchers, at Oregon Health and Science University, Beaverton, and the University of Colorado School of Medicine, Aurora, have found the offspring of both lean and obese nonhuman primate mothers chronically consuming a high-fat diet exhibited an increased risk of developing NAFLD. Importantly, if mothers fed a high-fat diet were reverted to a low-fat diet during a subsequent pregnancy, this second offspring exhibited fewer signs of NAFLD. The team, led by Kevin Grove and Jacob Friedman, therefore suggests that a developing fetus is highly susceptible to maternal consumption of excess fat, whether or not the mother is obese, and that a healthy maternal diet is most important for the obesity-related health of a developing fetus.

TITLE: Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates

AUTHOR CONTACT:
Kevin L. Grove
Oregon Health and Science University, Beaverton, Oregon, USA.
Phone: (503) 690-5380; Fax: (503) 690-5384; E-mail: grovek@ohsu.edu.

Jacob E. Friedman,
University of Colorado School of Medicine, Aurora, Colorado, USA.
Phone: (303) 724-3983; Fax: (303) 724-3920; E-mail: jed.friedman@ucdenver.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32661


ONCOLOGY: Antibodies targeting the protein Pim-1 inhibit cancer cell growth

In a number of human cancers, including prostate cancer, the protein Pim-1 has been found to be expressed more highly than in the corresponding noncancerous tissue. Pei Xiang Xing and colleagues, at Burnet Institute Incorporating Austin Research Institute, Australia, have now taken therapeutic advantage of this by generating an antibody that binds to Pim-1 and using it to inhibit the growth of human and mouse prostate cancer cell lines in mouse models of prostate cancer. Further in vitro analysis revealed that the antibody worked by inducing cancer cells to die and that it synergistically enhanced the antitumor effects of two chemotherapeutic drugs. The researchers therefore suggest that using antibodies that target Pim-1 might of benefit to individuals with prostate cancer.

TITLE: Pim-1specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis

AUTHOR CONTACT:
Pei Xiang Xing
Burnet Institute Incorporating Austin Research Institute, Heidelberg, Victoria, Australia.
Phone: 61-3-9287-0676; Fax: 61-3-9287-0600; E-mail: px.xing@burnet.edu.au.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33216


ONCOLOGY: Role for the protein FAK in breast cancer

A team of researchers, led by Filippo Giancotti and Yuliya Pylayeva, at Memorial Sloan-Kettering Cancer Center, New York, has provided new insight into the initiation, maintenance, and progression to metastasis of a specific subset of human and mouse breast cancers.

A marked proportion of breast cancers are associated with excessive activation of either Ras or PI3K signaling pathways, and many therapies aimed at disrupting these signaling pathways are under development. In this study, the FAK gene was found to be amplified in a substantial number of the human breast cancer samples analyzed. Consistent with this having a role in tumor development, mice lacking the Fak gene in breast tissue were protected in a model of breast cancer caused by excessive activation of Ras and PI3K. Further, silencing the FAK gene arrested the growth of human breast cancer cells with excessive activation of either Ras or PI3K signaling pathways. The authors therefore suggest that combined inhibition of FAK and either PI3K or Ras signaling may provide an effective approach for the treatment of breast cancer.

TITLE: Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling

AUTHOR CONTACT:
Filippo G. Giancotti
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Phone: (212) 639-7333; Fax: (212) 794-6236; E-mail: f-giancotti@ski.mskcc.org.

Yuliya Pylayeva
NYU School of Medicine, New York, New York, USA.
Phone: (212) 263-2937; Fax: (212) 263-8166; E-mail: pylayy01@nyumc.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=37160


HEMATOLOGY: No PKC-alpha protein, no inappropriate blood clot formation

The predominant cause of a heart attack is atherothrombosis, where a blood clot (otherwise known as a thrombus) forms in a blood vessel supplying the heart at the site of a ruptured or eroded atherosclerotic plaque (the entity that causes hardening or furring of the arteries). Platelets have a key role in the development of these blood clots, and the development of antithrombotic drugs that do not impair other functions of platelets, in particular their role in stopping bleeding, is therefore of immense interest. As Alastair Poole and colleagues, at the University of Bristol, United Kingdom, have found that mice lacking the protein PKC-alpha exhibited diminished thrombus formation in vivo but showed no evidence of overt bleeding, they suggest that PKC-alpha is a potential target for antithrombotic therapy. In particular, they propose that future studies should determine whether current drugs targeting PKC-alpha (e.g., aprinocarsen) are of benefit in the setting of atherothrombosis.

TITLE: PKC-alpha regulates platelet granule secretion and thrombus formation in mice

AUTHOR CONTACT:
Alastair W. Poole
University of Bristol, Bristol, United Kingdom.
Phone: 44-117-331-1435; Fax: 44-117-331-2288; E-mail: a.poole@bris.ac.uk.

View the PDF of this article at: https://www.the-jci.org/article.php?id=34665


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related biology news :

1. New online report on massive jellyfish swarms released
2. Powerful online tool for protein analysis provided pro bono by Stanford geneticist
3. Smithsonian puts tropical eastern Pacific shore fishes online
4. Smithsonian puts tropical Eastern-Pacific shore fishes online
5. Latin American Science Initiative Puts Tropical Rainforest Diversity Online
6. Personalized medicine: Innovative online journal leads the way
7. TGen spin-off MedTrust Online enables cancer doctors to quickly obtain best-available information
8. American Physical Society announces Physics, a new, free, online publication
9. Yale Environment 360 magazine launches online
10. Nonlinear ecosystem response points to environmental solutions
11. UF to auction naming rights for new butterfly species online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: